Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4823-4833
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4823
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4823
Table 1 Disease characteristics at baseline and history of inflammatory bowel disease-related therapy
| Biological therapy | |||||
| Vedolizumab % (n = 23) | Adalimumab % (n = 57) | Infliximab % (n = 42) | Ustekinumab % (n = 25) | ||
| Age at IBD diagnosis (yr) | < 60 | 69 (16) | 81 (46) | 71 (30) | 76 (19) |
| ≥ 60 | 30 (7) | 19 (11) | 28 12 | 24 (6) | |
| IBD type | CD | 52 (12) | 81 (46) | 64 (27) | 96 (24) |
| UC | 48 (11) | 19 (11) | 36 (15) | 4 (1) | |
| CD location | Ileal (L1) | 17 (4) | 24 (14) | 9 (4) | 12 (3) |
| Colonic (L2) | 4 (1) | 21 (12) | 19 (8) | 24 (6) | |
| Ileocolonic (L3) | 26 (6) | 31 (18) | 38 (16) | 48 (12) | |
| Isolated upper GI disease (L4) | 4 (1) | 3 (2) | 2 (1) | 4 (1) | |
| Combined upper GI disease with L1, 2 or 3 | 4 (1) | 2 (1) | 2 (1) | 12 (3) | |
| Disease behavior | Luminal (B1) | 17 (4) | 38 (22) | 24 (10) | 32 (8) |
| Stricturing (B2) | 26 (6) | 28 (16) | 28 (12) | 44 (11) | |
| Penetrating (B3) | 13 (3) | 16 (9) | 17 (7) | 24 (6) | |
| CD perianal | Presence of perianal disease | 9 (2) | 12 (7) | 24 (10) | 16 (4) |
| UC extension | Proctitis (E1) | 0 | 2 (1) | 0 | 0 |
| Left-sided (E2) | 26 (6) | 5 (3) | 5 (2) | 0 | |
| Pancolitis (E2) | 22 (5) | 12 (7) | 26 (11) | 4 (1) | |
| UC severity (Mayo score) | 1 | 13 (3) | 9 (5) | 5 (2) | 0 |
| 2 | 17 (4) | 7 (4) | 17 (7) | 0 | |
| 3 | 17 (4) | 3 (2) | 9 (4) | 4 (1) | |
| Charlson Comorbidity Index | 0 | 0 | 9 (5) | 5 (2) | 0 |
| 1-2 | 56 (13) | 54 (31) | 38 (16) | 36 (9) | |
| 3-4 | 26 (6) | 28 (16) | 48 (20) | 36 (9) | |
| More than 4 | 17 (4) | 9 (5) | 7 (3) | 28 (7) | |
| History of malignancy | Active within last 5 yr | 4 (1) | 3 (2) | 2 (1) | 8 (2) |
| Active more than 5 yr prior | 4 (1) | 2 (1) | 5 (2) | 0 | |
| Prior resective surgery | Surgical resection ≥ 1 | 43 (10) | 44 (25) | 33 (14) | 72 (18) |
| Previous exposure to biologics | Bio-naïve | 39 (9) | 54 (31) | 76 (32) | 20 (5) |
| Previous exposure to anti-TNF | 61 (14) | 46 (26) | 21 (9) | 80 (20) | |
| Previous exposure to VDZ | 0 | 0 | 7 (3) | 4 (1) | |
| Previous exposure to UST | 9 (2) | 0 | 2 (1) | 4 (1) | |
| Concomitancy of 5-ASA | Yes | 39 (9) | 14 (8) | 8 (19) | 16 (4) |
| Concomitancy of systemic steroids at baseline | Yes | 43 (10) | 26 (15) | 40 (17) | 40 (10) |
| Concomitancy of immunomodulator at baseline | Yes | 9 (2) | 17 (10) | 26 (11) | 8 (2) |
| History of an extraintestinal manifestation | Musculoskeletal | 0 | 3 (2) | 5 (2) | 4 (1) |
| Ocular | 0 | 3 (2) | 5 (2) | 8 (2) | |
| Mucocutaneous | 4 (1) | 3 (2) | 7 (3) | 12 (3) | |
| Primary sclerosing cholangitis | 4 (1) | 0 | 0 | 4 (1) | |
- Citation: Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. World J Gastroenterol 2022; 28(33): 4823-4833
- URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4823